Foresters Investment Management Company Inc. lowered its position in Pfizer Inc. (NYSE:PFE) by 12.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,639,656 shares of the biopharmaceutical company’s stock after selling 228,350 shares during the period. Pfizer comprises 1.4% of Foresters Investment Management Company Inc.’s holdings, making the stock its 5th largest position. Foresters Investment Management Company Inc.’s holdings in Pfizer were worth $71,571,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Advocacy Wealth Management Services LLC increased its holdings in Pfizer by 48.2% during the 4th quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 258 shares in the last quarter. Winch Advisory Services LLC boosted its stake in shares of Pfizer by 69.6% during the 4th quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 336 shares during the last quarter. 1 North Wealth Services LLC acquired a new position in shares of Pfizer during the 4th quarter worth about $40,000. Ruggie Capital Group acquired a new position in shares of Pfizer during the 4th quarter worth about $44,000. Finally, Contravisory Investment Management Inc. boosted its stake in shares of Pfizer by 182.6% during the 4th quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 745 shares during the last quarter. Institutional investors and hedge funds own 71.88% of the company’s stock.
In related news, insider Rady A. Johnson sold 8,700 shares of the firm’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $41.13, for a total value of $357,831.00. Following the completion of the sale, the insider now directly owns 59,797 shares in the company, valued at approximately $2,459,450.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $42.83, for a total transaction of $642,450.00. Following the completion of the sale, the insider now owns 124,994 shares of the company’s stock, valued at $5,353,493.02. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.
A number of equities analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, April 10th. Goldman Sachs Group assumed coverage on shares of Pfizer in a research note on Tuesday, May 28th. They set a “conviction-buy” rating for the company. Morgan Stanley assumed coverage on shares of Pfizer in a research note on Tuesday, June 4th. They set an “overweight” rating and a $48.00 price objective for the company. Barclays restated a “hold” rating and set a $41.00 price objective on shares of Pfizer in a research note on Thursday, May 9th. Finally, JPMorgan Chase & Co. set a $46.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, April 30th. Thirteen investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $46.00.
Shares of NYSE:PFE opened at $43.08 on Thursday. Pfizer Inc. has a 52-week low of $35.73 and a 52-week high of $46.47. The stock has a market capitalization of $239.77 billion, a P/E ratio of 14.36, a PEG ratio of 2.48 and a beta of 0.64. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.54 and a quick ratio of 1.27.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.10. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. The business had revenue of $13.12 billion during the quarter, compared to the consensus estimate of $13.01 billion. During the same period last year, the business posted $0.77 EPS. Pfizer’s revenue was up 1.6% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.89 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, June 7th. Investors of record on Friday, May 10th were paid a $0.36 dividend. The ex-dividend date was Thursday, May 9th. This represents a $1.44 annualized dividend and a yield of 3.34%. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.
ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2019/06/13/pfizer-inc-nysepfe-shares-sold-by-foresters-investment-management-company-inc.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: What is Cost of Debt?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.